2019 |
03/29 | 2,229 | 2,243 | 2,216 | 2,227 | +1.09% | 21,900 | 641億3760万 | -2.88% |
03/28 | 2,221 | 2,221 | 2,190 | 2,203 | -2.13% | 42,100 | 634億4640万 | -4.22% |
03/27 | 2,262 | 2,285 | 2,241 | 2,251 | -0.49% | 55,800 | 648億2880万 | -2.34% |
03/26 | (IR情報)17:00 譲渡制限付株式報酬としての自己株式の処分に関するお知らせ |
03/26 | (IR情報)15:00 支配株主等に関する事項について |
03/26 | 2,205 | 2,271 | 2,205 | 2,262 | +2.68% | 45,700 | 651億4560万 | -1.99% |
03/25 | 2,210 | 2,258 | 2,200 | 2,203 | -0.81% | 55,500 | 634億4640万 | -4.55% |
03/22 | 2,276 | 2,276 | 2,221 | 2,221 | -3.52% | 64,000 | 639億6480万 | -3.77% |
03/20 | 2,362 | 2,362 | 2,291 | 2,302 | -2.54% | 59,300 | 662億9760万 | -0.22% |
03/19 | 2,382 | 2,398 | 2,356 | 2,362 | -0.71% | 16,800 | 680億2560万 | +2.56% |
03/18 | 2,383 | 2,410 | 2,356 | 2,379 | 0% | 48,000 | 685億1520万 | +3.57% |
03/15 | 2,374 | 2,432 | 2,364 | 2,379 | +0.93% | 84,600 | 685億1520万 | +3.98% |
03/14 | 2,317 | 2,465 | 2,316 | 2,357 | +3.97% | 201,400 | 678億8160万 | +3.42% |
03/13 | 2,237 | 2,288 | 2,237 | 2,267 | +0.09% | 31,400 | 652億8960万 | -0.7% |
03/12 | 2,201 | 2,275 | 2,201 | 2,265 | +3.9% | 33,900 | 652億3200万 | -1.13% |
03/12 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 134,600株(0.46%)-0.13%義務消失 |
03/11 | 2,183 | 2,219 | 2,168 | 2,180 | +0.97% | 29,400 | 627億8400万 | -5.26% |
03/08 | 2,202 | 2,223 | 2,152 | 2,159 | -3.49% | 35,600 | 621億7920万 | -6.54% |
03/07 | 2,250 | 2,281 | 2,225 | 2,237 | -1.76% | 33,300 | 644億2560万 | -3.58% |
03/06 | 2,301 | 2,321 | 2,251 | 2,277 | -1.64% | 44,700 | 655億7760万 | -2.11% |
03/05 | 2,330 | 2,345 | 2,306 | 2,315 | -1.74% | 13,500 | 666億7200万 | -0.73% |
03/04 | 2,330 | 2,411 | 2,330 | 2,356 | +1.03% | 28,000 | 678億5280万 | +0.9% |
03/01 | (IR情報)15:00 JAK阻害剤「JTE-052(デルゴシチニブ)軟膏」の国内第3相臨床試験(比較試験)で得られた成績の米国皮膚科学会での発表について |
03/01 | 2,319 | 2,364 | 2,319 | 2,332 | +0.17% | 20,700 | 671億6160万 | -0.3% |
02/28 | 2,365 | 2,380 | 2,326 | 2,328 | -1.23% | 34,900 | 670億4640万 | -0.6% |
02/27 | 2,360 | 2,381 | 2,331 | 2,357 | -0.51% | 50,200 | 678億8160万 | +0.47% |
02/26 | 2,375 | 2,386 | 2,340 | 2,369 | -0.71% | 19,000 | 682億2720万 | +0.81% |
02/25 | 2,380 | 2,394 | 2,354 | 2,386 | +1.1% | 27,300 | 687億1680万 | +1.32% |
02/22 | 2,386 | 2,386 | 2,302 | 2,360 | -1.34% | 38,700 | 679億6800万 | +0.08% |
02/21 | 2,437 | 2,446 | 2,357 | 2,392 | +2.35% | 61,700 | 688億8960万 | +1.23% |
02/20 | 2,305 | 2,337 | 2,285 | 2,337 | +1.08% | 24,300 | 673億560万 | -1.27% |
02/19 | 2,290 | 2,317 | 2,261 | 2,312 | +2.44% | 42,300 | 665億8560万 | -2.61% |
02/18 | 2,230 | 2,292 | 2,230 | 2,257 | +2.13% | 65,100 | 650億160万 | -5.29% |
02/15 | 2,166 | 2,211 | 2,153 | 2,210 | +0.36% | 29,000 | 636億4800万 | -7.72% |
02/14 | 2,186 | 2,213 | 2,142 | 2,202 | +0.09% | 29,600 | 634億1760万 | -8.55% |
02/13 | 2,235 | 2,235 | 2,182 | 2,200 | -0.36% | 43,600 | 633億6000万 | -9.13% |
02/12 | 2,173 | 2,209 | 2,156 | 2,208 | +2.65% | 65,000 | 635億9040万 | -9.29% |
02/08 | 2,090 | 2,177 | 2,080 | 2,151 | -0.19% | 92,600 | 619億4880万 | -12.02% |
02/07 | 2,225 | 2,235 | 2,132 | 2,155 | -12.82% | 223,500 | 620億6400万 | -12.26% |
02/06 | (IR情報)15:00 代表取締役および役員等の異動に関するお知らせ |
02/06 | (IR情報)15:00 特別転身支援制度の実施について |
02/06 | (IR情報)15:00 「注射用フサン10」、「注射用フサン50」の製造販売承認の承継について |
02/06 | (IR情報)15:00 特別損失(事業構造改革費用)の計上及び2018年12月期通期業績予想と実績との差異に関するお知らせ |
02/06 | (IR情報)15:00 「中期経営計画2021」の策定のお知らせ |
02/06 | (IR情報)15:00 2018年12月期決算参考資料 |
02/06 | (IR情報)15:00 2018年12月期決算短信〔日本基準〕(非連結) |
02/06 | 2,436 | 2,532 | 2,436 | 2,472 | +0.61% | 50,300 | 711億9360万 | +0.08% |
02/05 | 2,506 | 2,525 | 2,431 | 2,457 | -1.96% | 35,700 | 707億6160万 | -0.41% |
02/05 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 171,000株(0.59%)-0.01% |
02/04 | 2,423 | 2,507 | 2,423 | 2,506 | +3.85% | 27,300 | 721億7280万 | +1.7% |
02/01 | 2,386 | 2,427 | 2,383 | 2,413 | +0.58% | 25,800 | 694億9440万 | -2.03% |
01/31 | (IR情報)15:00 JAK阻害剤「JTE-052(デルゴシチニブ)軟膏」の日本国内における製造販売承認申請について |
01/31 | 2,392 | 2,413 | 2,388 | 2,399 | +0.46% | 31,600 | 690億9120万 | -2.84% |
01/30 | 2,402 | 2,409 | 2,386 | 2,388 | -1.73% | 65,400 | 687億7440万 | -3.63% |
01/29 | 2,409 | 2,436 | 2,393 | 2,430 | +0.87% | 27,800 | 699億8400万 | -2.25% |
01/28 | 2,448 | 2,449 | 2,402 | 2,409 | -1.35% | 34,200 | 693億7920万 | -3.45% |
01/25 | 2,493 | 2,503 | 2,436 | 2,442 | +1.37% | 51,900 | 703億2960万 | -2.51% |
01/25 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 172,800株(0.6%)+0.02% |
01/24 | 2,401 | 2,443 | 2,397 | 2,409 | -0.33% | 32,500 | 693億7920万 | -4.21% |
01/23 | 2,453 | 2,460 | 2,400 | 2,417 | -2.38% | 45,400 | 696億960万 | -4.16% |
01/22 | 2,499 | 2,517 | 2,446 | 2,476 | -0.4% | 24,000 | 713億880万 | -1.9% |
01/21 | 2,484 | 2,519 | 2,483 | 2,486 | +0.61% | 21,000 | 715億9680万 | -1.43% |
01/18 | 2,467 | 2,507 | 2,467 | 2,471 | +0.2% | 14,800 | 711億6480万 | -1.98% |
01/17 | 2,506 | 2,517 | 2,460 | 2,466 | -1.52% | 33,800 | 710億2080万 | -2.38% |
01/16 | 2,533 | 2,533 | 2,494 | 2,504 | -0.71% | 24,900 | 721億1520万 | -0.95% |
01/15 | 2,488 | 2,596 | 2,486 | 2,522 | -0.28% | 27,600 | 726億3360万 | -0.32% |
01/11 | 2,530 | 2,534 | 2,472 | 2,529 | -0.82% | 36,900 | 728億3520万 | -0.08% |
01/10 | 2,550 | 2,566 | 2,529 | 2,550 | 0% | 22,400 | 734億4000万 | +0.59% |
01/09 | 2,521 | 2,572 | 2,514 | 2,550 | +1.15% | 41,800 | 734億4000万 | +0.99% |
01/08 | 2,491 | 2,545 | 2,474 | 2,521 | +0.4% | 41,100 | 726億480万 | +0.2% |
01/07 | 2,562 | 2,588 | 2,495 | 2,511 | +0.97% | 37,400 | 723億1680万 | +0.12% |
01/04 | 2,408 | 2,493 | 2,385 | 2,487 | +2.22% | 37,700 | 716億2560万 | -0.48% |
2018 |
12/28 | 2,498 | 2,499 | 2,415 | 2,433 | -2.68% | 16,000 | 700億7040万 | -2.37% |
12/27 | 2,467 | 2,500 | 2,407 | 2,500 | +3.95% | 46,100 | 720億 | +0.56% |
12/26 | 2,361 | 2,447 | 2,361 | 2,405 | +1.18% | 50,600 | 692億6400万 | -2.99% |
12/25 | 2,439 | 2,439 | 2,365 | 2,377 | -4.5% | 43,600 | 684億5760万 | -4.08% |
12/21 | 2,543 | 2,543 | 2,417 | 2,489 | -2.16% | 50,300 | 716億8320万 | +0.36% |
12/20 | 2,602 | 2,627 | 2,543 | 2,544 | -3.23% | 43,700 | 732億6720万 | +2.75% |
12/19 | 2,570 | 2,685 | 2,537 | 2,629 | +1.12% | 72,800 | 757億1520万 | +6.44% |
12/18 | 2,600 | 2,631 | 2,562 | 2,600 | -1.66% | 46,900 | 748億8000万 | +5.65% |
12/17 | 2,635 | 2,698 | 2,623 | 2,644 | -0.68% | 48,200 | 761億4720万 | +7.83% |
12/14 | (IR情報)16:00 抗HIV薬6品の日本国内における独占的販売権に関する契約の終了日確定のお知らせ |
12/14 | 2,685 | 2,685 | 2,642 | 2,662 | -0.75% | 51,300 | 766億6560万 | +8.96% |
12/13 | 2,600 | 2,719 | 2,600 | 2,682 | +3.55% | 95,800 | 772億4160万 | +10.23% |
12/13 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 169,800株(0.58%)-0.02% |
12/12 | 2,499 | 2,620 | 2,483 | 2,590 | +4.9% | 98,800 | 745億9200万 | +6.98% |
12/11 | 2,445 | 2,499 | 2,400 | 2,469 | +2.07% | 47,100 | 711億720万 | +2.32% |
12/10 | 2,524 | 2,524 | 2,412 | 2,419 | -2.22% | 70,400 | 696億6720万 | +0.5% |
12/07 | 2,507 | 2,536 | 2,340 | 2,474 | -4.29% | 176,900 | 712億5120万 | +3% |
12/06 | 2,536 | 2,589 | 2,523 | 2,585 | +2.3% | 50,500 | 744億4800万 | +7.93% |
12/05 | 2,524 | 2,567 | 2,517 | 2,527 | -0.47% | 43,300 | 727億7760万 | +5.69% |
12/04 | 2,516 | 2,584 | 2,510 | 2,539 | -0.59% | 79,400 | 731億2320万 | +6.32% |
12/03 | 2,480 | 2,591 | 2,480 | 2,554 | -2.89% | 251,600 | 735億5520万 | +7.09% |
11/30 | 2,350 | 2,666 | 2,350 | 2,630 | +14.15% | 520,300 | 757億4400万 | +10.5% |
11/29 | (IR情報)15:00 抗HIV薬6品の日本国内における独占的販売権に関する契約の終了について |
11/29 | 2,330 | 2,349 | 2,301 | 2,304 | -1.12% | 23,200 | 663億5520万 | -2.91% |
11/28 | 2,314 | 2,349 | 2,310 | 2,330 | +0.69% | 20,100 | 671億400万 | -2.22% |
11/27 | 2,299 | 2,319 | 2,283 | 2,314 | +0.65% | 26,600 | 666億4320万 | -3.22% |
11/26 | 2,275 | 2,321 | 2,275 | 2,299 | +0.39% | 27,000 | 662億1120万 | -4.25% |
11/26 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 174,079株(0.6%)+0.1% |
11/22 | 2,228 | 2,306 | 2,228 | 2,290 | -0.26% | 83,100 | 659億5200万 | -5.1% |
11/21 | 2,327 | 2,327 | 2,295 | 2,296 | -1.54% | 43,800 | 661億2480万 | -5.32% |
11/20 | 2,372 | 2,372 | 2,323 | 2,332 | -2.02% | 23,800 | 671億6160万 | -4.27% |
11/19 | 2,397 | 2,398 | 2,370 | 2,380 | -1.37% | 34,100 | 685億4400万 | -2.66% |
11/16 | 2,393 | 2,429 | 2,386 | 2,413 | +0.84% | 20,700 | 694億9440万 | -1.59% |
11/15 | 2,381 | 2,406 | 2,379 | 2,393 | -0.5% | 19,300 | 689億1840万 | -2.64% |
11/14 | 2,402 | 2,409 | 2,363 | 2,405 | +0.97% | 44,000 | 692億6400万 | -2.43% |
11/13 | 2,377 | 2,402 | 2,366 | 2,382 | -0.38% | 38,100 | 686億160万 | -3.72% |
11/12 | 2,390 | 2,408 | 2,373 | 2,391 | -0.71% | 17,300 | 688億6080万 | -3.9% |
11/09 | 2,419 | 2,471 | 2,407 | 2,408 | -0.86% | 25,100 | 693億5040万 | -3.83% |
11/08 | 2,410 | 2,456 | 2,410 | 2,429 | +2.23% | 29,300 | 699億5520万 | -3.5% |
11/07 | 2,378 | 2,408 | 2,362 | 2,376 | -0.25% | 27,600 | 684億2880万 | -6.05% |
11/06 | 2,377 | 2,420 | 2,371 | 2,382 | +2.19% | 36,200 | 686億160万 | -6.22% |
11/05 | 2,331 | 2,372 | 2,296 | 2,331 | +1.97% | 64,300 | 671億3280万 | -8.7% |
11/02 | 2,311 | 2,320 | 2,260 | 2,286 | -0.61% | 119,700 | 658億3680万 | -11.05% |
11/01 | 2,637 | 2,637 | 2,300 | 2,300 | -7.52% | 128,400 | 662億4000万 | -11.09% |
11/01 | (空売り報告)Integrated Core Strategies (Asia) Pte. Ltd. 145,000株(0.5%)新規 |
10/31 | (IR情報)15:00 2018年12月期第3四半期決算参考資料 |
10/31 | (IR情報)15:00 平成30年12月期第3四半期決算短信〔日本基準〕(非連結) |
10/31 | 2,453 | 2,526 | 2,453 | 2,487 | +1.72% | 38,400 | 716億2560万 | -4.49% |
10/30 | 2,431 | 2,482 | 2,421 | 2,445 | -0.45% | 45,100 | 704億1600万 | -6.47% |